A particularly promising target for antigen-specific immunotherapy in MM and other B-cell malignancies is the B-cell maturation antigen (BCMA, TNFRSF17, CD269), a member of the tumor necrosis receptor superfamily. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.